+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Primary Immune Deficiency (PID) Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

  • ID: 4768163
  • Report
  • April 2019
  • Region: Global
  • 112 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • Baxter International Inc
  • Creat Group Corp
  • CSL Ltd
  • GlaxoSmithKline Plc
  • Green Cross Holdings Corp
  • Grifols SA
  • MORE
The global clinical trial report- “2019 Primary Immune Deficiency (PID) Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Primary Immune Deficiency (PID). It presents in-depth analysis of Primary Immune Deficiency (PID) clinical trials across markets and companies. The research work is for providing complete understanding into trends in Primary Immune Deficiency (PID).

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Primary Immune Deficiency (PID) clinical trials by:
  • Current Trial Status
  • Type of the trial
  • Sponsor Type
  • Enrollment Trends
  • Region
  • Countries
  • Trial Phase
The report also identifies the potential drug candidates under development for treatment of Primary Immune Deficiency (PID)

The research work is prepared through extensive and continuous research on Primary Immune Deficiency (PID) trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:
  • All major trials from 2010 to 2019 and planned trials are included in the report scope.
  • Drug candidates currently being researched for administering Primary Immune Deficiency (PID) patients are identified
  • The report includes panorama of Primary Immune Deficiency (PID) clinical trials across the globe
  • Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
  • Companies and universities focusing on Primary Immune Deficiency (PID) clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
  • Average Enrollment number, insights into enrollment trends, company wise enrollment are included
  • Both interventional and observational studies are analyzed
  • News and latest developments for the past one year are presented in the report
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Baxter International Inc
  • Creat Group Corp
  • CSL Ltd
  • GlaxoSmithKline Plc
  • Green Cross Holdings Corp
  • Grifols SA
  • MORE
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 Primary Immune Deficiency (PID) Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
2.2.1 Primary Immune Deficiency (PID) Clinical Trials by Region
2.2.2 Average Enrollment of Primary Immune Deficiency (PID) Clinical Trials
2.2.3 Companies participating in Trials
2.2.4 Drugs under Study for Primary Immune Deficiency (PID) Treatment, 2019

3. Region wise Primary Immune Deficiency (PID) Clinical Trials
3.1 Asia Pacific Primary Immune Deficiency (PID) Clinical Trials by Country
3.2 Europe Primary Immune Deficiency (PID) Clinical Trials by Country
3.3 North America Primary Immune Deficiency (PID) Clinical Trials by Country
3.4 Middle East and Africa Primary Immune Deficiency (PID) Clinical Trials by Country
3.5 South and Central America Primary Immune Deficiency (PID) Clinical Trials by Country

4. Primary Immune Deficiency (PID) Clinical Trial Trends
4.1 Start Year wise Primary Immune Deficiency (PID) Clinical Trials
4.2 Phase wise Primary Immune Deficiency (PID) Clinical Trials
4.3 Trial Status wise Primary Immune Deficiency (PID) Clinical Trials
4.4 Trial Type wise Primary Immune Deficiency (PID) Clinical Trials

5. Primary Immune Deficiency (PID) Average Enrollment Trends
5.1 Average Enrollment in Primary Immune Deficiency (PID) Trials by Year
5.2 Average Enrollment in Primary Immune Deficiency (PID) Trials by Phase
5.3 Average Enrollment in Primary Immune Deficiency (PID) Trials by Status
5.4 Average Enrollment in Primary Immune Deficiency (PID) Trials by Type of Trial

6. Companies Participating in Primary Immune Deficiency (PID) Clinical Trials
6.1 Primary Immune Deficiency (PID) Trials by Sponsor Type
6.2 Primary Immune Deficiency (PID) Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7. Trial Snapshots- Phase, Type, Title, Location, Start Year, Completion Year, Recruitment Status, Enrollment, Participating Countries, Trial Locations, Company, Drugs and Other Details
7.1 Primary Immune Deficiency (PID) Trials- Phase 1
7.2 Primary Immune Deficiency (PID) Trials- Phase 2
7.3 Primary Immune Deficiency (PID) Trials- Phase 3
7.4 Primary Immune Deficiency (PID) Trials- Phase 4

8. Appendix
8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List of Figures
Figure 1: Primary Immune Deficiency (PID) Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific - Country wise Primary Immune Deficiency (PID) Clinical Trials and Enrolment
Figure 5: Europe - Country wise Primary Immune Deficiency (PID) Clinical Trials and Enrolment
Figure 6: Middle East Africa - Country wise Primary Immune Deficiency (PID) Clinical Trials and Enrolment
Figure 7: North America - Country wise Primary Immune Deficiency (PID) Clinical Trials and Enrolment
Figure 8: South and Central America - Country wise Primary Immune Deficiency (PID) Clinical Trials and Enrolment
Figure 9: Primary Immune Deficiency (PID) Clinical Trials by Phase
Figure 10: Primary Immune Deficiency (PID) Clinical Trials by Trial Status
Figure 11: Primary Immune Deficiency (PID) Clinical Trials by Type
Figure 12: Primary Immune Deficiency (PID) Clinical Trials by Sponsor Type
Figure 13: Primary Immune Deficiency (PID) Clinical Trials by Leading Sponsors
Figure 14: Primary Immune Deficiency (PID) Average Enrollment by Phase
Figure 15: Primary Immune Deficiency (PID) Average Enrollment by Trial Status
Figure 16: Primary Immune Deficiency (PID) Average Enrollment by Type
Figure 17: Primary Immune Deficiency (PID)- Average Enrolment by Type of Sponsors
Figure 18: Primary Immune Deficiency (PID)- Enrolment by Leading Sponsors
Figure 19: Research Methodology

List of Tables
Table 1: Primary Immune Deficiency (PID) Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific - Country wise Primary Immune Deficiency (PID) Clinical Trials and Enrolment
Table 5: Europe - Country wise Primary Immune Deficiency (PID) Clinical Trials and Enrolment
Table 6: Middle East Africa - Country wise Primary Immune Deficiency (PID) Clinical Trials and Enrolment
Table 7: North America - Country wise Primary Immune Deficiency (PID) Clinical Trials and Enrolment
Table 8: South and Central America - Country wise Primary Immune Deficiency (PID) Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Primary Immune Deficiency (PID) Average Enrollment by Phase
Table 15: Primary Immune Deficiency (PID) Average Enrollment by Trial Status
Table 16: Primary Immune Deficiency (PID) Average Enrollment by Type
Table 17: Primary Immune Deficiency (PID)- Average Enrolment by Type of Sponsors
Table 18: Primary Immune Deficiency (PID)- Enrolment by Leading Sponsors
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Baxter International Inc
  • Bellicum Pharmaceuticals Inc
  • Creat Group Corp
  • CSL Ltd
  • GlaxoSmithKline Plc
  • Green Cross Holdings Corp
  • Grifols SA
  • Ministry of Health France
  • Octapharma AG
  • Shire Plc
Note: Product cover images may vary from those shown
Adroll
adroll